Insider Buying: Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires 207,100 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Scott Sandell bought 207,100 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the transaction, the insider owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Korro Bio Price Performance

NASDAQ:KRRO traded down $0.26 during trading hours on Thursday, reaching $11.50. The company had a trading volume of 92,041 shares, compared to its average volume of 184,676. The firm has a market cap of $108.33 million, a PE ratio of -1.22 and a beta of 2.98. The business’s 50 day moving average price is $10.90 and its 200-day moving average price is $20.23. Korro Bio, Inc. has a 1-year low of $5.20 and a 1-year high of $55.89.

Korro Bio (NASDAQ:KRRO) last announced its earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter. Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%.The business had revenue of $1.29 million for the quarter. On average, analysts expect that Korro Bio, Inc. will post -9.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on KRRO shares. Raymond James Financial set a $18.00 price target on shares of Korro Bio in a research report on Wednesday, February 18th. HC Wainwright reiterated a “neutral” rating on shares of Korro Bio in a research note on Thursday, November 13th. William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Piper Sandler downgraded shares of Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 price objective for the company. in a research note on Thursday, November 13th. Finally, Clear Str upgraded shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $50.38.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new position in shares of Korro Bio in the 4th quarter valued at $4,806,000. TCG Crossover Management LLC purchased a new stake in Korro Bio during the 3rd quarter worth approximately $19,937,000. Vanguard Group Inc. raised its holdings in Korro Bio by 2.3% in the third quarter. Vanguard Group Inc. now owns 395,659 shares of the company’s stock valued at $18,948,000 after acquiring an additional 8,921 shares in the last quarter. Polar Capital Holdings Plc increased its holdings in Korro Bio by 5.9% in the third quarter. Polar Capital Holdings Plc now owns 264,694 shares of the company’s stock valued at $12,676,000 after buying an additional 14,694 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Korro Bio by 1.8% during the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after acquiring an additional 4,650 shares in the last quarter. 13.18% of the stock is owned by hedge funds and other institutional investors.

Key Korro Bio News

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Multiple major shareholders and investors materially bought stock on March 10 — including Anthony A. Florence Jr., Paul E. Walker, Mohamad Makhzoumi, Edward T. Mathers, Forest Baskett, Rick Yang, Scott D. Sandell and Enterprise Associates 17 New — each acquiring 207,100 shares at $11.11, increasing their individual stakes by ~18.99%. Insider and large‑holder purchases often signal confidence in company prospects. SEC Filing (example)
• Positive Sentiment: Company reported an oversubscribed $85 million private placement that management says extends the cash runway into H2 2028 — reduces near‑term financing risk and supports ongoing programs. The corporate update also cited nominations of development candidates (KRRO‑121 for hyperammonemia indications and an advanced GalNAc conjugate program for alpha‑1 antitrypsin deficiency), indicating R&D progress. GlobeNewswire Press Release
• Negative Sentiment: Quarterly results were weak: KRRO reported a Q4 EPS loss of $(5.32), far worse than the consensus loss of $(1.93), with only $1.29M in revenue and a deeply negative net margin and ROE. The magnitude of the miss raises execution and cost concerns and likely pressured the stock despite the financing and insider buying. Zacks Coverage of Q4 Results

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.